Sen. Mike Crapo (R-ID): Pharmaceutical PAC money and a record of opposing Medicare drug pricing
Sen. Mike Crapo (R-ID) received $253,400 from pharmaceutical PACs between 2017 and 2022 and, as Finance Committee chairman, has consistently opposed Medicare drug price negotiation.
Sen. Mike Crapo (R-ID) received at least $253,400 from pharmaceutical and health product political action committees between 2017 and 2022. During that same period, he voted against legislation authorizing Medicare to negotiate lower drug prices and blocked a Senate vote on a separate drug pricing bill. Since becoming chairman of the Senate Finance Committee in January 2025, the committee with direct jurisdiction over Medicare drug policy, Crapo has continued to oppose price negotiation measures. A 2025 law whose drug pricing provisions fall within his committee’s purview gave the pharmaceutical industry an exemption that the Congressional Budget Office valued at $8.8 billion.
The Donors
Campaign finance disclosures show pharmaceutical companies have been consistent supporters of Crapo’s Senate campaigns. A review of Federal Election Commission records published by Forbes found that Crapo received $119,000 from pharmaceutical company PACs between 2009 and 2018. The companies whose PACs contributed during that window, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson and Johnson, Merck, Pfizer, and Sanofi, were appearing before the Senate Finance Committee to discuss drug pricing during the same period.
Contributions continued at a higher rate in subsequent years. Between 2017 and 2022, Crapo received $253,400 from pharmaceutical and health product PACs, according to data from OpenSecrets compiled by Common Dreams. His PAC fundraising also surged around the time he was positioned to take the Finance Committee chairmanship, with PAC contributions in the final quarter of 2020 far exceeding those of any comparable prior period.
The Votes
On February 9, 2022, Sen. Bernie Sanders (I-VT) sought unanimous consent to advance the Cutting Medicare Prescription Drug Prices in Half Act, which would have required Medicare to negotiate drug prices to match rates paid by the Department of Veterans Affairs. Crapo objected, preventing the bill from advancing to debate or a formal vote. He described the proposal as one that would “usher in more bureaucracy.”
Six months later, on August 7, 2022, the Senate passed the Inflation Reduction Act 51-50, with Vice President Kamala Harris casting the tie-breaking vote. The law gave Medicare the authority to negotiate prices for a subset of high-cost drugs for the first time. All 50 Republican senators voted against it. Crapo said in a statement that the drug price negotiation provisions “risk reversing decades of progress on bringing lifesaving treatments and medical breakthroughs to American patients.”
Crapo was named chairman of the Senate Finance Committee on January 7, 2025. Upon taking the position, he stated that conducting oversight of the Inflation Reduction Act’s health care provisions would be a committee priority.
In July 2025, Congress passed and President Trump signed the One Big Beautiful Bill Act. The law revised the Inflation Reduction Act’s drug pricing framework, exempting certain drugs from Medicare price negotiation. Drugs approved for only rare diseases were permanently removed from negotiation eligibility. Drugs initially approved for rare diseases but later approved for common conditions had their negotiation timelines extended.
The Cost to Patients
The Congressional Budget Office found that the drug pricing exemptions and delays in the One Big Beautiful Bill provided the pharmaceutical industry with an $8.8 billion benefit, nearly double an earlier estimate, according to Senate Finance Committee Democrats who sought to reverse the provisions.
The exemptions affected specific blockbuster drugs with large Medicare spending footprints. Keytruda, a Merck cancer drug, accounted for $13.5 billion in Medicare spending in 2024 and had its price negotiation delayed to 2027 under the new law. Darzalex, a Johnson and Johnson multiple myeloma treatment that cost Medicare approximately $5.6 billion in 2024, was permanently exempted from negotiation. The Congressional Budget Office estimated the changes would cost Medicare at least $5 billion over 10 years.
For Medicare beneficiaries, who typically pay 20 percent of covered drug costs out of pocket, delays or exemptions from price negotiation translate directly into higher expenses. For a drug like Keytruda, which treats lung cancer and other conditions, seniors face thousands of dollars in additional annual costs under the current pricing structure compared to what negotiations could produce.
Nearly 90 percent of Republican voters support allowing Medicare to negotiate drug prices, according to polling cited by Common Dreams, a figure that cuts across the partisan divide on this issue.
What You Can Do
Idaho residents can contact Sen. Crapo’s Washington office at (202) 224-6142 or submit a message through his official Senate website. For information on contacting your representatives and tracking drug pricing legislation, visit our take action page.
Sources
- Common Dreams — Crapo pharma PAC donations 2017-2022 and IRA vote
- Deseret News / Forbes FEC review — Crapo pharma PAC donations 2009-2018
- ClearNewswire — Crapo blocks Sanders drug pricing vote, February 2022
- Senate Finance Committee — Crapo named chairman, January 7, 2025
- Senate Finance Committee — Wyden et al. on $8.8 billion pharma exemption in One Big Beautiful Bill
- Finance and Money — One Big Beautiful Bill drug pricing changes, Keytruda and Darzalex details